[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. Ca A Cancer Journal for Clinicians, 2015, 60:277-300.
[2] Tsujikawa H, Masugi Y, Yamazaki K, et al. Immuno-histochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness. Human pathology, 2016, 50:24-33.
[3] Jin Y, Chen J, Feng Z, et al. The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma. Tumor Biology, 2014, 35:9905-9910.
[4] Yang X, Feng M, Jiang X, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb–E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes & Development, 2009, 23:2388-2393.
[5] Kim SS, Nam JS, Cho HJ, et al. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 2016, 32:199-207.
[6] Feng Y, Dong YW, Song YN, et al. MiR-449a is a potential predictor of colitis-associated colorectal cancer progression. Oncology Reports, 2018, 40:1684-1694.
[7] Wenting L, Bo H, Zixuan L, et al. MiR-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS ONE, 2013, 8:e64759-.
[8] Zhang EB, Kong R, Yin DD, et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget, 2014, 5:2276-2292.
[9] Liu S, Liu K, Zhang W, et al. miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma. Am J Transl Res, 2016, 8:2609-2619. |
